Takeda Pharmaceutical Non-GAAP EPS of ¥428.00, revenue of ¥3411.2B; updates FY26 outlook
Source: SeekingAlpha
2026-01-29 01:51:15 ET
More on Takeda Pharmaceutical
- Takeda Pharmaceutical Company Limited (TAK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Takeda Pharmaceutical Company Limited (TAK) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Takeda: Lack Of Realistic Upside In Japanese Pharma
- Halozyme, Takeda in arrangement to use former's drug delivery tech in Entyvio
- Takeda, XOMA ink new royalty agreement; amend existing deal
Read the full article on Seeking Alpha
For further details see:
Takeda Pharmaceutical Non-GAAP EPS of ¥428.00, revenue of ¥3411.2B; updates FY26 outlook
Takeda Pharmaceutical Company Limited American Depositary Shares
NASDAQ: TAK
TAK Trading
0.17% G/L:
$17.85 Last:
1,296,138 Volume:
$17.92 Open:
TAK Latest News
March 02, 2026 02:00:00 am
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
February 24, 2026 09:35:00 am
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
TAK Stock Data
$57,107,745,653
3,115,826,299
N/A
157
N/A
Pharmaceuticals
Healthcare
JP
Chuo-ku
